[1]冒平,王乙锠,王拓,等.下调TTK表达改善胶质母细胞瘤裸鼠的生存预后[J].中国临床神经外科杂志,2022,27(10):841-847.[doi:10.13798/j.issn.1009-153X.2022.10.013]
　MAO Ping,WANG Yi-chang,WANG Tuo,et al.Down-regulation of TTK improves the survival prognoses of nude mice bearing intracranial glioblastoma xenografts[J].,2022,27(10):841-847.[doi:10.13798/j.issn.1009-153X.2022.10.013]
点击复制

下调TTK表达改善胶质母细胞瘤裸鼠的生存预后()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
27
期数:
2022年10期
页码:
841-847
栏目:
实验研究
出版日期:
2022-10-31

文章信息/Info

Title:
Down-regulation of TTK improves the survival prognoses of nude mice bearing intracranial glioblastoma xenografts
文章编号:
1009-153X（2022）10-0841-07
作者:
冒平; 王乙锠; 王拓; 杜昌旺; 王茂德
710061西安，西安交通大学第一附属医院神经外科（冒平、王乙锠、王拓、杜昌旺、王茂德）
Author(s):
MAO Ping;  WANG Yi-chang;  WANG Tuo;  DU Chang-wang;  WANG Mao-de
Department of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China
关键词:
胶质母细胞瘤; 苏氨酸/酪氨酸激酶（TTK）; 裸鼠; 细胞增殖; 生存预后
Keywords:
Glioblastoma;  Threonine/tyrosine kinase (TTK);  Cell proliferation;  Survival prognosis;  Nude mice
分类号:
R739.41
DOI:
10.13798/j.issn.1009-153X.2022.10.013
文献标志码:
A
摘要:
目的 探讨苏氨酸/酪氨酸激酶（TTK）在胶质母细胞瘤（GBM）中的表达变化及其作用。方法计算机检索TCGA数据库，利用生物信息学技术分析GBM组织TTK的表达水平及其与病人生存预后的关系。免疫组化染色分析我院生物样本库中60例脑胶质瘤组织的TTK表达水平。体外培养U251细胞，慢病毒转染构建TTK低表达细胞系，利用Alarma blue试剂盒测定细胞增殖能力，细胞克隆形成实验检测细胞克隆形成能力，流式细胞技术检测细胞凋亡和细胞周期。将不同TTK表达水平的U251细胞接种裸鼠构建移植瘤模型，分析TTK表达水平与移植瘤模型生存期的关系。结果生信分析结果显示，GBM组织TTK表达水平明显高于低级别胶质瘤及正常脑组织（P<0.05），TTK低表达GBM病人的总生存期更长（P<0.05）。我院60例胶质瘤中，高级别胶质瘤TTK高表达率（69.0%，29/42）明显高于低级别胶质瘤（16.7%，3/18；P<0.05）。下调TTK表达明显抑制U251细胞增殖、促进细胞凋亡（P<0.05）。TTK低表达裸鼠移植瘤模型的生存期明显延长（P<0.05）。结论 GBM组织TTK呈高水平表达，具有促进细胞增殖及抑制细胞凋亡的作用，与GBM的不良预后相关。
Abstract:
Objective To investigate the expression and role of threonine/tyrosine kinase (TTK) in glioblastoma (GBM). Methods The TCGA database was searched by computer, and the expression level of TTK in GBM tissuesand its relationship with the prognosis of patients were analyzed by bioinformatics methods. Immunohistochemical staining was used to analyze the expression of TTK in 60 glioma tissues obtained from our hospital biobank. U251 cells were cultured in vitro and transfected with lentivirus to construct TTK low expression cell line. Alarma blue kit was used to detect cell proliferation, cell clone formation assay was used to detect cell clone formation, and flow cytometry was used to detect cell apoptosis and cell cycle. U251 cells with different TTK expression levels were transplanted into nude mice to establish xenograft tumor models, and the relationship between TTK expression levels and the survival of xenograft tumor models was analyzed. Results The results of bioinformatics analysis showed that the expression level of TTK in GBM tissues was significantly higher than that in low-grade glioma and normal brain tissues (P<0.05), and the overall survival time of GBM patients with low TTK expression was significantly longer (P<0.05). Of 60 glioma obtained from our hospital biobank, the high expression rate of TTK in high-grade gliomas (69.0%, 29/42) was significantly higher than that in low-grade gliomas (16.7%, 3/18; P<0.05). Down-regulation of TTK expression significantly inhibited the proliferation and promoted apoptosis of U251 cells (P<0.05). The survival time of TTK low expression xenograft model of nude mice was significantly prolonged (P<0.05). Conclusions The high level of TTK expression in GBM tissue can promote cell proliferation and inhibit cell apoptosis, which is related to the poor prognosis of GBM.

参考文献/References:

[1]刘宝辉，孙　前，袁凡恩，等. 高级别胶质瘤的治疗进展[J]. 中国临床神经外科杂志，2021，26（5）：380-384.
[2]Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radio-therapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial [J]. Lancet Oncol, 2009, 10(5): 459-466.
[3]Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial [J]. JAMA, 2015, 314(23): 2535-2543.
[4]Goenka A, Tiek D, Song X, et al. The many facets of therapy resistance and tumor recurrence in glioblastoma [J]. Cells, 2021, 10(3): 484.
[5]Murugan AK. mTOR: role in cancer，metastasis and drug resistance [J]. Semin Cancer Biol, 2019, 59: 92-111.
[6]Ghosh S, Marrocco I, Yarden Y. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment [J]. Adv Cancer Res, 2020, 147: 1-57.
[7]King JL, Zhang B, Li Y, et al. TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer [J]. Oncogenesis, 2018, 7(9): 69.
[8]Huang H, Yang Y, Zhang W, et al. TTK regulates proliferation and apoptosis of gastric cancer cells through the Akt-mTOR pathway [J]. FEBS Open Bio, 2020, 10(8): 1542-1549.
[9]Kaistha BP, Honstein T, Müller V, et al. Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells [J]. Br J Cancer, 2014, 111(9): 1780-1787.
[10]Chandler BC, Moubadder L, Ritter CL, et al. TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination [J]. J Clin Invest, 2020, 130(2): 958-973.
[11]Zhang H, Yao W, Zhang M, et al. TTK inhibitor promotes radiosensitivity of liver cancer cells through p21 [J]. Biochem Biophys Res Commun, 2021, 550: 84-91.
[12]Chen S, Wang J, Wang L, et al. Silencing TTK expression inhibits the proliferation and progression of prostate cancer [J]. Exp Cell Res, 2019, 385(1): 111669.
[13]Zhang N, Wei P, Gong A, et al. FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis [J]. Cancer Cell, 2011, 20(4): 427-442.
[14]Wang J, Yang T, Xu G, et al. Cyclin-dependent kinase 2 promotes tumor proliferation and induces radio resistance in glioblastoma [J]. Transl Oncol, 2016, 9(6): 548-556.
[15]Wang Q, Hu B, Hu X, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immuno-logical changes in the microenvironment [J]. Cancer Cell, 2017, 32(1): 42-56.
[16]Payne AW, Pant DK, Pan TC, et al. Ceramide kinase promotes tumor cell survival and mammary tumor recurrence [J]. Cancer Res, 2014, 74(21): 6352-6363.
[17]Liang XD, Dai YC, Li ZY, et al. Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma [J]. PLoS One, 2014, 9(6): e97739.
[18]Pachis ST, Kops GJPL. Leader of the SAC: molecular mechanisms of Mps1/TTK regulation in mitosis [J]. Open Biol, 2018, 8(8): 180109.
[19]Karoulia Z, Gavathiotis E, Poulikakos PI. New perspectives for targeting RAF kinase in human cancer [J]. Nat Rev Cancer, 2017, 17(11): 676-691.
[20]Markham A，Keam SJ. Selumetinib: first approval [J]. Drugs, 2020, 80(9): 931-937.
[21]Stratford JK, Yan F, Hill RA, et al. Genetic and pharmaco-logical inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability [J]. PLoS One, 2017, 12(4): e0174863.
[22]Uitdehaag JCM, de Man J, Willemsen-Seegers N, et al. Target residence time-guided optimization on TTK kinase results in inhibitors with potent anti-proliferative activity [J]. J Mol Biol, 2017, 429(14): 2211-2230.
[23]Schulze VK, Klar U, Kosemund D, et al. Treating cancer by spindle assembly checkpoint abrogation: discovery of two clinical candidates, BAY 1161909 and BAY 1217389, targeting MPS1 kinase [J]. J Med Chem, 2020, 63(15): 8025-8042.
[24]Chen S, Wang Y, Ni C, et al. HLF/miR-132/TTK axis regulates cell proliferation, metastasis and radiosensitivity of glioma cells [J]. Biomed Pharmacother, 2016, 83: 898-904.
[25]Wang J, Xie Y, Bai X, et al. Targeting dual specificity protein kinase TTK attenuates tumorigenesis of glioblastoma [J]. Oncotarget, 2018, 9(3): 3081-3088.

相似文献/References:

[1]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(10):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述　高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强　杨吉安　邵灵敏　吴庭枫　刘宝辉　陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
　LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(10):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇　冯　军　黄俊红　白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
　GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(10):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕　孟凡华　刘魏然　魏春晓　林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
　WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(10):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元　王汉东　樊友武　贾　玥　吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
　ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(10):69.
[7]郑锐哲　姜秀峰　陈二涛　孙兆良　冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
　HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(10):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安　陆　南　贺亚龙　章　翔　刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
　YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(10):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴　蛟　易　勇　赵卓琳　周良学　周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
　WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(10):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]

备注/Memo

备注/Memo:
（2022-03-20收稿，2022-07-19修回）
基金项目：国家自然科学基金（82072781）
更新日期/Last Update: 2022-11-30